MEDICAL HONEY WOUND DRESSING BUSINESS PLAN

I. Executive Summary

Company Description

Apis BioHeal—named for Apis, the Latin word for bee—operates in the medical device and advanced wound care industry, developing and manufacturing medical-grade honey wound dressings. We produce sterile, cGMP-compliant, FDA-registered dressings at our major U.S. medical hub facility for the 2026 healthcare market. Our core products are bioactive, antibiotic-free dressings that combine validated antimicrobial honey formulations with sterile dressing substrates to speed healing and reduce infection. One-liner: We turn proven natural bioactivity into FDA-ready sterile wound care.

We focus on R&D, sterile manufacturing, regulatory strategy, and clinical sales to deliver hospital- and clinic-ready products. What sets us apart is a team with biochemistry, regulatory affairs, and clinical sales expertise plus a manufacturing line tuned for sterile, scalable runs—yielding consistent potency and shorter time-to-market versus small-scale competitors. Target customers are hospitals, wound-care clinics, long-term care facilities, and specialty distributors treating chronic and acute wounds. Short-term goals: complete regulatory filings, validate commercial-scale production, and secure initial distributor contracts by Q4 2026. Long-term goals: national hospital formulary adoption, global export approvals, and a 5-year target of 25% market share in bioactive dressing segments. One-liner: We aim to replace antibiotics in key wound pathways with a scalable, science-backed honey therapy.

Problem

Chronic and acute wounds in the U.S. heal slowly and are highly prone to infection, increasing patient morbidity and healthcare use. In 2026 clinicians face rising rates of antibiotic-resistant bacteria, which make standard topical and systemic antibiotics less reliable. Existing wound care options lack widely adopted dressings with proven natural antimicrobial potency that reduce bioburden without systemic antibiotics, leading to longer treatment times, more clinic visits, higher costs, and greater risk of complications.

There is a clear need for sterile, medical-grade wound dressings produced in an FDA-registered, cGMP-compliant facility that offer validated, antibiotic-free antimicrobial action to shorten healing, cut readmissions, and reduce reliance on systemic antibiotics.

Solution

Chronic and acute wounds in the U.S. drive infections, longer hospital stays, and rising costs as traditional care often fails, especially with antibiotic resistance and complex cases like diabetic ulcers. Our offering addresses this gap with a line of advanced wound dressings that deliver a non-systemic antimicrobial option tailored to varied wound needs.

The product portfolio—Honey Pads, Honey Gels, Honey Gauze, Honey Strips, and Honey Foams—is infused with medical-grade honey to provide antimicrobial and anti-inflammatory activity, maintain a moist healing environment, and reduce scarring; each unit is produced in an FDA-compliant facility for sterility and consistent potency. One clear result: effective topical infection management without systemic antibiotics.

Mission Statement

Our mission is to revolutionize wound care by providing healthcare professionals with natural, scientifically supported honey-based dressings that accelerate recovery and reduce infection. We commit to sterility, quality, and clinical efficacy in every product, to educate clinicians, and to partner with health systems to make medical-grade honey a standard of care in the U.S. We pursue effective healing that is ecologically responsible and measurable in patient outcomes.

Key Success Factors

Success depends on product differentiation, regulatory compliance, fast unit economics, channel access, and clinical adoption.

• Proprietary honey-infusion process: provides unique product efficacy and defensible manufacturing IP.
• FDA and ISO compliance: ensures market access to hospitals and long-term procurement contracts.
• Rapid breakeven (2 months): delivers early profitability and cash flow for scaling.
• National distributor relationships: secure placement in acute and long-term care facilities nationwide.
• Clinical education program: drives high adoption rates and realizes the $40.5M revenue potential.

Financial Summary

The company projects rapid scale from first-year revenue of $2,290,000 and EBITDA $519,000 in 2026 to a 2030 run rate of $40,500,000 revenue and $29,070,000 EBITDA.

Financial requirements include a minimum cash buffer of $744,000 (required Aug-26); payback on initial investment is 15 months; reported returns include IRR 14.59% and ROE 61.6%.

Outlook: strong growth, high margins, and investor returns above typical manufacturing benchmarks.

Funding Requirements

We seek $2,770,000 to fund capital equipment, first-year operations, marketing, and a minimum cash reserve so the business can start commercial production in 2026.

Projected first-year revenue of $2,290,000 with $519,000 EBITDA, scaling to $40,500,000 revenue and $29,070,000 EBITDA by 2030, with a 14.59% IRR, 61.6% ROE, and a 15-month payback on the initial investment.